Acumen Pharmaceuticals, Inc. Operating Income
Acumen Pharmaceuticals, Inc. (ABOS) reported Operating Income of -$32.56 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-12
- Acumen Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$32.56M.
- Acumen Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$21.15M.
- Acumen Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$25.20M.
- Acumen Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$26.51M.
- Acumen Pharmaceuticals, Inc. operating income (loss) for fiscal 2025 was -$123.83M.
- Acumen Pharmaceuticals, Inc. operating income (loss) for fiscal 2024 was -$114.02M.
- Acumen Pharmaceuticals, Inc. operating income (loss) for fiscal 2023 was -$61.14M.
- Acumen Pharmaceuticals, Inc. operating income (loss) for fiscal 2022 was -$45.24M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$32.56M 10-Q · filed 2026-08-12 | -$53.70M 10-Q · filed 2026-08-12 | -$78.90M derived: sum of 3 quarters · filed 2026-08-12 | -$105.42M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$21.15M 10-Q · filed 2026-05-12 | -$46.35M derived: sum of 2 quarters · filed 2026-05-12 | -$72.86M derived: sum of 3 quarters · filed 2026-05-12 | -$114.61M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$25.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$51.71M derived: sum of 2 quarters · filed 2026-03-26 | -$93.46M derived: sum of 3 quarters · filed 2026-08-12 | -$123.83M 10-K · filed 2026-03-26 |
| 2025-09-30 | -$26.51M 10-Q · filed 2025-11-12 | -$68.26M derived: sum of 2 quarters · filed 2026-08-12 | -$98.63M 10-Q · filed 2025-11-12 | -$138.23M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$41.75M 10-Q · filed 2026-08-12 | -$72.12M 10-Q · filed 2026-08-12 | -$111.72M derived: sum of 3 quarters · filed 2026-08-12 | -$143.98M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$30.37M 10-Q · filed 2026-05-12 | -$69.97M derived: sum of 2 quarters · filed 2026-05-12 | -$102.23M derived: sum of 3 quarters · filed 2026-05-12 | -$126.61M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$39.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$71.86M derived: sum of 2 quarters · filed 2026-03-26 | -$96.24M derived: sum of 3 quarters · filed 2026-03-26 | -$114.02M 10-K · filed 2026-03-26 |
| 2024-09-30 | -$32.27M 10-Q · filed 2025-11-12 | -$56.65M derived: sum of 2 quarters · filed 2025-11-12 | -$74.42M 10-Q · filed 2025-11-12 | -$92.91M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$24.38M 10-Q · filed 2025-08-12 | -$42.16M 10-Q · filed 2025-08-12 | -$60.64M derived: sum of 3 quarters · filed 2025-08-12 | -$76.68M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$17.77M 10-Q · filed 2025-05-13 | -$36.26M derived: sum of 2 quarters · filed 2025-05-13 | -$52.30M derived: sum of 3 quarters · filed 2025-05-13 | -$65.78M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$18.49M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$34.52M derived: sum of 2 quarters · filed 2025-03-27 | -$48.00M derived: sum of 3 quarters · filed 2025-03-27 | -$61.14M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$16.04M 10-Q · filed 2024-11-12 | -$29.52M derived: sum of 2 quarters · filed 2024-11-12 | -$42.65M 10-Q · filed 2024-11-12 | -$56.90M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$13.48M 10-Q · filed 2024-08-13 | -$26.61M 10-Q · filed 2024-08-13 | -$40.86M derived: sum of 3 quarters · filed 2024-08-13 | -$52.23M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$13.13M 10-Q · filed 2024-05-14 | -$27.38M derived: sum of 2 quarters · filed 2024-05-14 | -$38.75M derived: sum of 3 quarters · filed 2024-05-14 | -$49.16M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$14.25M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$25.62M derived: sum of 2 quarters · filed 2024-03-26 | -$36.03M derived: sum of 3 quarters · filed 2024-03-26 | -$45.24M 10-K · filed 2024-03-26 |
| 2022-09-30 | -$11.37M 10-Q · filed 2023-11-13 | -$21.78M derived: sum of 2 quarters · filed 2023-11-13 | -$30.99M 10-Q · filed 2023-11-13 | -$39.40M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$10.41M 10-Q · filed 2023-08-08 | -$19.62M 10-Q · filed 2023-08-08 | -$28.03M derived: sum of 3 quarters · filed 2023-08-08 | -$31.97M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$9.21M 10-Q · filed 2023-05-09 | -$17.62M derived: sum of 2 quarters · filed 2023-05-09 | -$21.56M derived: sum of 3 quarters · filed 2023-05-09 | -$25.00M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$8.41M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | -$12.35M derived: sum of 2 quarters · filed 2023-03-27 | -$15.79M derived: sum of 3 quarters · filed 2023-03-27 | -$19.58M 10-K · filed 2023-03-27 |
| 2021-09-30 | -$3.94M 10-Q · filed 2022-11-14 | -$7.38M derived: sum of 2 quarters · filed 2022-11-14 | -$11.17M 10-Q · filed 2022-11-14 | -$12.51M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$3.44M 10-Q · filed 2022-08-15 | -$7.23M 10-Q · filed 2022-08-15 | -$8.57M derived: sum of 3 quarters · filed 2022-08-15 | -$11.06M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | -$3.79M 10-Q · filed 2022-05-16 | -$5.13M derived: sum of 2 quarters · filed 2022-05-16 | -$7.62M derived: sum of 3 quarters · filed 2022-05-16 | -$9.66M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$3.83M derived: sum of 2 quarters · filed 2022-03-28 | -$5.87M derived: sum of 3 quarters · filed 2022-03-28 | -$7.91M 10-K · filed 2022-03-28 |
| 2020-09-30 | -$2.49M 10-Q · filed 2021-11-15 | -$4.53M derived: sum of 2 quarters · filed 2021-11-15 | -$6.57M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | -$2.04M 10-Q · filed 2021-08-16 | -$4.08M 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |